| dbo:abstract |
سيديليزوماب هو جسم مضاد وحيد النسيلة يؤثر على الجهاز المناعي. الاستخدامات الممكنة قد تكون في زراعة الأعضاء لمنع رفض الطعم، وعلاج أمراض المناعة الذاتية. (ar) Cedelizumab is a monoclonal antibody acting on the immune system. Possible indications include the prevention of organ transplant rejections and the treatment of autoimmune diseases. It has been approved by both the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of patients with moderate-to-severe Crohn's disease (CD) and ulcerative colitis (UC). Vedolizumab is a humanized monoclonal antibody, which binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7) on T lymphocytes to interfere with lymphocyte trafficking to the gut. (en) |
| dbo:casNumber |
156586-90-2 |
| dbo:kegg |
D03420 |
| dbo:wikiPageID |
9124403 (xsd:integer) |
| dbo:wikiPageLength |
2514 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1059873659 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Ulcerative_colitis dbr:Integrin_alpha_4 dbr:Integrin_beta_7 dbr:Peyer's_patch dbr:Crohn's_disease dbr:Monoclonal_antibody dbr:Protein_dimer dbc:Monoclonal_antibodies dbr:Autoimmune_disease dbr:CD4 dbr:Integrin dbr:Immune_system dbr:Organ_transplant dbr:T_lymphocyte |
| dbp:atcPrefix |
none (en) |
| dbp:casNumber |
156586 (xsd:integer) |
| dbp:chemspiderid |
none (en) |
| dbp:kegg |
D03420 (en) |
| dbp:mabType |
mab (en) |
| dbp:source |
zu/o (en) |
| dbp:target |
dbr:CD4 |
| dbp:type |
mab (en) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
458638966 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Antineoplastic-drug-stub dbt:Drugbox dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Keggcite dbt:Monoclonals_for_immune_system dbt:Immunosuppressants dbt:Monoclonal-antibody-stub |
| dct:subject |
dbc:Monoclonal_antibodies |
| gold:hypernym |
dbr:Antibody |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459 umbel-rc:DrugProduct |
| rdfs:comment |
سيديليزوماب هو جسم مضاد وحيد النسيلة يؤثر على الجهاز المناعي. الاستخدامات الممكنة قد تكون في زراعة الأعضاء لمنع رفض الطعم، وعلاج أمراض المناعة الذاتية. (ar) Cedelizumab is a monoclonal antibody acting on the immune system. Possible indications include the prevention of organ transplant rejections and the treatment of autoimmune diseases. It has been approved by both the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of patients with moderate-to-severe Crohn's disease (CD) and ulcerative colitis (UC). (en) |
| rdfs:label |
سيديليزوماب (ar) Cedelizumab (en) |
| owl:sameAs |
freebase:Cedelizumab yago-res:Cedelizumab wikidata:Cedelizumab dbpedia-ar:Cedelizumab dbpedia-vi:Cedelizumab https://global.dbpedia.org/id/4gZyn |
| prov:wasDerivedFrom |
wikipedia-en:Cedelizumab?oldid=1059873659&ns=0 |
| foaf:isPrimaryTopicOf |
wikipedia-en:Cedelizumab |
| is dbo:wikiPageWikiLink of |
dbr:List_of_therapeutic_monoclonal_antibodies dbr:List_of_drugs:_Cb–Ce |
| is foaf:primaryTopic of |
wikipedia-en:Cedelizumab |